Literature DB >> 32553561

Comparison of morphological features in lymph node metastasis between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinomas.

Daigoro Takahashi1, Motohiro Kojima2, Ryo Morisue1, Motokazu Sugimoto1, Shin Kobayashi1, Shinichiro Takahashi1, Masaru Konishi1, Naoto Gotohda1, Masafumi Ikeda3, Atsushi Ochiai4.   

Abstract

BACKGROUND: Various studies have reported inconsistent results regarding the use of lymph node size for the prediction of metastasis in pancreatic cancer. Further, there is even less information in pNENs. Thus, the clinical accuracy and utility of using lymph node size to predict lymph node metastasis in pNENs has not been fully elucidated
OBJECTIVES: This study aimed to examine differences in lymph node morphology between pancreatic neuroendocrine neoplasms (pNENs) and pancreatic ductal adenocarcinomas (PDACs) to create more accurate diagnostic criteria for lymph node metastasis.
METHODS: We assessed 2139 lymph nodes, 773 from pNEN specimens and 1366 from PDAC specimens, surgically resected at our institute between 1994 and 2016. We evaluated the number, shape, size, and presence of metastasis.
RESULTS: Sixty-eight lymph nodes from 16 pNEN patients and 109 lymph nodes from 33 PDAC patients were metastatic. There were more lymph nodes sampled per case in the PDAC group than in the pNEN group (31.8 vs. 18.0). Metastatic lymph nodes in pNEN patients were larger and rounder than those in PDAC patients (minor axis: 5.15 mm vs. 3.11 mm; minor axis/major axis ratio: 0.701 vs. 0.626). The correlation between lymph node size and metastasis was stronger in pNENs (r = 0.974) than in PDACs (r = 0.439).
CONCLUSIONS: Lymph node status and morphology are affected by differences in tumor histology. The lymph node minor axis is a reliable parameter for the prediction of lymph node metastasis and has more utility as a predictive marker in pNENs than in PDACs.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Diagnosis; Imaging; Lymph node metastasis; Neuroendocrine neoplasms; Pancreatic cancer

Mesh:

Year:  2020        PMID: 32553561     DOI: 10.1016/j.pan.2020.05.013

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  1 in total

1.  Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center.

Authors:  Zuowei Wu; Pengcheng Zhao; Zihe Wang; Xing Huang; Chao Wu; Mao Li; Li Wang; Bole Tian
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.